Showing results (61-70 of 271) with videos related to
Sort By:
Pageof 28
Clinical Trials (London, England)|June 28, 2017
Group sequential designs for stepped-wedge cluster randomised trialsMichael J Grayling, James Ms Wason, Adrian P ManderJournal of the Royal Statistical Society. Series C, Applied Statistics|March 19, 2019
A Bayesian model-free approach to combination therapy phase I trials using censored time-to-toxicity dataGraham M Wheeler, Michael J Sweeting, Adrian P ManderBiometrical Journal. Biometrische Zeitschrift|October 7, 2025
Multivariate Bayesian Dynamic Borrowing for Repeated Measures Data With Application to External Control Arms in Open-Label Extension StudiesBenjamin F Hartley, Matthew A Psioda, Adrian P ManderStatistics in Medicine|March 16, 2017
Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trialsGraham M Wheeler, Michael J Sweeting, Adrian P ManderStatistics in Medicine|January 22, 2022
Response adaptive intervention allocation in stepped-wedge cluster randomized trialsMichael J Grayling, James M S Wason, Sofía S VillarContemporary Clinical Trials|April 11, 2025
Efficient stage-wise allocation ratios in multi-arm multi-stage designsRuqayya A Azher, Michael J Grayling, James M S WasonJournal of the National Cancer Institute|June 21, 2019
A Review of Perspectives on the Use of Randomization in Phase II Oncology TrialsMichael J Grayling, Munyaradzi Dimairo, Adrian P Mander, et al.BMC Rheumatology|December 7, 2021
Increasing power in the analysis of responder endpoints in rheumatology: a software tutorialMartina McMenamin, Michael J Grayling, Anna Berglind, et al.Biometrics|January 15, 2021
Two-stage penalized regression screening to detect biomarker-treatment interactions in randomized clinical trialsJixiong Wang, Ashish Patel, James M S Wason, et al.Biometrical Journal. Biometrische Zeitschrift|January 24, 2007
Trial designs for targeted therapiesSimon G ThompsonPageof 28